Crowell C, Mankuzhy NP, Bennett J, Bandopadhayay P, Sturm D, Green AL, Gupta T, Chatterjee A, Epari S, Chinnaswamy G, Prasad M, Patel SH, MacNeil M, Vanan MI, Larouche V, Renzi S, Jones J, Perreault S, Mata-Mbemba D, Sangatsuda Y, Yoshimoto K, Lin E, Feddersen C, Cruz O, Pavon-Mengual M, Vizzini O, Zápotocký M, Popovacki A, Klawinski D, Hansford JR, Schlosser MP, Omene E, Alexander KL, Satgunaseelan L, Williams A, Yao K, Ronsley R, Cheng S, Ludlow L, Eisenstat D, Khuong-Quang DA, Tabouret E, André N, Matheson K, Chan A, Lim-Fat MJ, Lapointe S, Cayrol R, Coleman C, Juretic N, McThenia S, Khan S, Wright-Nadkarni M, Salloum R, Galvin RT, Sener U, Hawkins C, Imber BS, Karajannis MA, Jones DTW, Ligon KL, Jabado N, Erker C. Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study. Clin Cancer Res. 2026 Jun 01; 32(11):2243-2254.

Wooten E, Chon NL, Dzhalolov M, Zheng H, Lin H. Protonation States of Proton-Sensing Glutamate Residues in Transporter Sialin. Int J Mol Sci. 2026 May 21; 27(10).

Crooke ST, Glass S, Gleeson JG, Mignon L, Skourti-Stathaki K, Douville J, Knutsen M, Pu H, Bain JM, Berry-Kravis E, Shneider NA, Kim-McManus O, Eichler FS, Chung WK, Nagy A, Kaufmann H, Gonzalez-Duarte A, Oskarsson B, McCourt EA, Leung N. Addressing the needs of nano-rare patients: the n-Lorem experience. Nucleic Acids Res. 2026 May 20; 54(10).

Mead EH, Batz KC, Shih KH, Fleming IR, Tesdahl CD, Lizardos L, Armendariz JR, Hannan JP, Hickey AM, Leyk A, Erbse AH, Falke JJ. COSMIC-Linked Ras Mutations at the Interface Between H-Ras and PI3K?RBD Frequently Generate Affinity Increases. Biochemistry. 2026 Jun 02; 65(11):1749-1754.

Sekrecki M, Sekrecka A, Lattupally RR, Le K, Jin X, Mozes C, Dwyer BG, Zhuang Z, Romero BA, Pineda JMB, Cao X, Nguyen L, Chen V, Zhou CM, Wallace JA, Tanaka K, Tiwari C, Gabel A, Kim WJ, Stanley RF, Benbarche S, Thind J, Muruganandham A, Zhang TY, Greenberg PL, Gotlib JR, Mannis G, Shomali WE, Salmasi G, Kuo C, Shanafelt T, Singh I, Inoue D, Hansen FK, Gray NS, van Rechem C, Fakhri B, Zhang X, Lu SX. Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability. Blood. 2026 Apr 23; 147(17):1941-1957.

Erdem S, Haliloglu Y, Uslu IN, Houran M, Ulutabanca H, Vural A, Erturhan MB, Canatan H, Eken A. IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression. Inflamm Res. 2026 Apr 01; 75(1).

Galassi Deforie V, Maroofian R, Karagoz I, Godwin A, Al Sheikh E, Gestri G, Zaki MS, Woodward BL, Ghorab RM, Alvi JR, Alabdi L, Damseh N, Elshafie RM, Scardamaglia A, Alves C, Shaikh M, Özcan GG, Sadek AA, Issa MY, Striano P, Suri M, Murphy D, Ashhab M, de la Fuente RP, Arteche-López A, Hashem MO, Abdulwahab F, Aboelanine AH, Alkhawaja IA, Ibrahim S, van der Burg M, Berghuis D, Santen GW, Toosi MB, Alerasool M, Eslahi A, Srinivasan VM, Gowda VK, Trollmann R, Vasileiou G, Pauly M, Hashemi-Gorji F, Miryounesi M, Salpietro V, Al-Herz W, Carter SP, Briggs TA, Hussell T, Ruuska-Loewald T, Komulainen-Ebrahim J, Uusimaa J, Hautala T, Potluri S, Shackley F, Mojarrad M, Chung WK, Wilson SW, Sultan T, Gleeson JG, Marafi D, Alkuraya FS, Stewart GS, Efthymiou S, Guille M, Arkwright PD, Houlden H. Recessive loss of DIAPH1 function causes a progressive neurodevelopmental syndrome with variable immunological involvement. Genet Med. 2026 May; 28(5):102551.

Waliany S, Cooper AJ, Liu SV, Gautschi O, Rotow JK, Smith KER, Weber UM, Lee DH, Loong HHF, Patel JD, Pennell NA, Nagasaka M, Patel SA, Tan DSW, Solomon BJ, Kim TM, Pall G, Riess JW, Sun L, Früh M, Uy NF, Gadgeel S, Feng J, Do A, Falcon C, Leighl NB, Baik CS, Lai GGY, Ou SI, Cheung KSY, Patil T, Mansfield AS, Weiler D, Yeap BY, Wirth LJ, Gainor JF, Drilon A, Lin JJ. Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. Clin Cancer Res. 2026 Mar 16; 32(6):1157-1168.

Collier AE, Hilz S, Chibly AM, Duan C, Pasquina LW, Sun X, Chavez-MacGregor M, Bardia A, Martín M, Lim E, Sohn J, Pérez-Moreno PD, Fernando TM, Moore HM. ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer. Nat Commun. 2026 Mar 12; 17(1).

Fountzilas C, Rosario S, Witkiewicz AK, Withers HG, Bajor DL, Mukherjee S, Saltzman J, Maguire O, Minderman H, Chatley S, Tarquini ML, Whitworth A, Jurcevic J, Hsiao HH, Knudsen ES, Muhitch JB, Abrams SI, Kalinski P, Segal BH, Bakin A, Yuan G, Wang C, Attwood K, Iyer R, Boland PM. TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab. Int J Cancer. 2026 Jun 15; 158(12):3300-3311.